<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119168">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675570</url>
  </required_header>
  <id_info>
    <org_study_id>CTD1201</org_study_id>
    <nct_id>NCT01675570</nct_id>
  </id_info>
  <brief_title>A Study of RX-10045 in the Treatment of Dry Eye Disease</brief_title>
  <official_title>A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Masked Study of RX-10045 (0.09%) in the Treatment of Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C.T. Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C.T. Development America, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the efficacy, tolerability and safety of
      RX-10045 Ophthalmic Solution in patients with Dry Eye Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Corneal staining</measure>
    <time_frame>Baseline to day 28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Worst symptom score</measure>
    <time_frame>Baseline to day 28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular discomfort symptom score</measure>
    <time_frame>Baseline to day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear film break-up time</measure>
    <time_frame>Baseline to day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual-related function subscale of Ocular Surface Disease Index score</measure>
    <time_frame>Baseline to day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>RX-10045 active arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RX-10045 Opththalmic Solution, 0.09%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle for RX-10045 arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of RX-10045 Ophthalmic Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10045</intervention_name>
    <description>One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.</description>
    <arm_group_label>RX-10045 active arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle for RX-10045</intervention_name>
    <description>One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.</description>
    <arm_group_label>Vehicle for RX-10045 arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a patient reported history of dry eye in both eyes

          2. Presence of dry eye symptoms

          3. Presence of dry eye signs, destabilized tear film break-up time and corneal staining

        Exclusion Criteria:

          1. Known contraindications or sensitivities to study medication or its components

          2. Any ocular condition that, in the opinion of the investigator, could affect the
             subject's safety or trial parameters

          3. Use of disallowed medication during the period indicated prior to the enrollment or
             during the study

          4. Be a female who is currently pregnant, planning a pregnancy, lactating, or not using
             a medically acceptable form of birth control
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andover Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 7, 2013</lastchanged_date>
  <firstreceived_date>August 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RX-10045</keyword>
  <keyword>Dry Eye Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
